In treatment-naïve patients with vision impairment due to DME
Rapid, early vision gains in Year 1, maintained through to Year 31,2
EYLEA® is the EURETINA guidelines DME drug of choice in patients with baseline BCVA <69 letters3,a
Superior to ranibizumab in Year 13,4
Anti-VEGF Cochrane meta-analysis
DME patients are 30% more likely to gain ≥3 lines vs. ranibizumab in Year 15,b,c
a These EURETINA Guidelines included data from Protocol T where the dose of ranibizumab tested was 0.3 mg (US-approved dosage), while the ex-US dosage of ranibizumab is 0.5 mg. The treatment regimen tested in Protocol T was not the label regimen for either EYLEA or ranibizumab.
b Meta-analysis using Cochrane methods (based on a search of databases conducted in April 2017) of RCTs with anti-VEGF agents in DME patients, focused on the three most commonly used drugs: EYLEA, ranibizumab and unlicensed bevacizumab. The analysis included 24 studies and 6007 eyes in total. 17 studies (4031 eyes) were assessed for VA data.
c This Cochrane meta-analysis included data from Protocol T where the dose of ranibizumab tested was 0.3 mg (US approved dosage) while the ex-US dosage of ranibizumab is 0.5 mg. The treatment regimen tested in Protocol T was not the label regimen for either EYLEA or ranibizumab.
BCVA, best-corrected visual acuity; DME, diabetic macular edema; Q8, 2 mg every-8-weeks; RCT, randomized controlled trial; VA, visual acuity.
- Korobelnik J-F, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247-2254.
- Heier JS, Korobelnik JF, Brown DM. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. Ophthalmology. 2016;123(11):2376-2385.
- Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185-222.
- Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193-1203.
- Virgili G, Parravano M, Evans JR, et al. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2017;6:CD007419.